S. Steiner1, Sandra Ferreira1, Moran Morelli1, Audrey Baldi1, Arkadiusz K. Kuczaj1, Stefan Frentzel1, Marco van der Toorn1, Manuel Peitsch1, Julia Hoeng1
1 PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchâtel, Switzerland
This poster shows the investigation how aerosols are delivered within the Cloud SEQ 24 and how cell cultures respond to exposures in the system. Ibuprofen and Bortezomib was exposed to three dimensional organotypic tissue cultures of the human bronchial epithelium and biological endpoints were measured: Cytotoxicity, Interleukin 8 and Proteasome activity.
Introduction and Objectives
The Vitrocell® Cloud SEQ 24 System is an advanced version of the Vitrocell® Cloud 6 and the Vitrocell® 12, a series of aerosol exposure systems specifically designed for delivering aerosols generated from liquid test matrices to cell cultures under controlled and reproducible conditions. It allows exposing 24 cell cultures of the 24-well format simultaneously and in addition provides a feature for sequential dosing, which decreases the need for cell culture handling, and thereby increases system efficacy and throughput. Whereas the Vitrocell® Cloud 6 has been characterized in detail (Lenz et al 2014), little is known about how aerosols are delivered within the Cloud SEQ 24 and how cell cultures respond to exposures in the system. We therefore conducted system characterization in cell free experiments and by exposing three-dimensional organotypic tissue cultures of the human bronchial epithelium to a non steroidal anti-inflammatory drug (Ibuprofen) and the proteasome inhibitor Bortezomib. Special attention was thereby put on the system’s ability to deliver the test aerosols in a repeatable and uniform manner and to trigger test compound specific biological responses.
